A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Hodgkin's disease; Lymphoma
- Focus Adverse reactions
- 21 Dec 2018 Planned End Date changed from 1 Jul 2020 to 1 Nov 2019.
- 12 Jul 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
- 12 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2020.